Tarsa Therapeutics, Inc.

Merck & Co. Inc. 's termination of its Phase III post-menopausal osteoporosis drug odanacatib due to stroke risk means the loss of a potential primary care blockbuster. Merck announced Sept. 2 that i

The potential for Radius Health Inc. 's abaloparatide to better improve hip bone mass and have a lower risk of hypercalcemia than earlier osteoporosis drugs "may be important distinguishing features

The potential for Radius Health Inc. 's abaloparatide to better improve hip bone mass and have a lower risk of hypercalcemia than earlier osteoporosis drugs "may be important distinguishing features

Amgen Inc. and UCB Group have appeared to lock in their head start in the race to get new osteoporosis biologics market, with the July 21 announcement that they had submitted the biologics licen